Reprise Biomedical, Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-11.
Reprise Biomedical, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 11, 2025. The filing reports $6.36M sold. Its industry group is Biotechnology. It names Carrie Powers (Executive Officer, Director), Jake Isenburg (Executive Officer), Tom Kouchoukos (Executive Officer) (SEC Form D, July 11, 2025).
Is this your company?
Sell to companies like Reprise Biomedical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Reprise Biomedical, Inc.
Free to see. No signup.
More on the people and the money behind Reprise Biomedical, Inc., from the filings we hold.
Cedar Point Capital, LLC received sales compensation on this raise and on 6 other raises we hold, nearest in date first:
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Reprise Biomedical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Reprise Biomedical, Inc. raises, hires or launches. No email unless you switch it on.
Watch Reprise Biomedical, Inc. →Get the full cited report on Reprise Biomedical, Inc.
What the filing shows about Reprise Biomedical, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Reprise Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Reprise Biomedical, Inc.'s address as 17400 Medina Rd., Ste. 100, Plymouth, MN 55447.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Reprise Biomedical, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Reprise Biomedical, Inc. See pricing
Reprise Biomedical, Inc. is a registered filer with the SEC (CIK 1782236) and has filed since 2023-01-03. 7 filings are on record, the latest on 2026-07-01.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Reprise Biomedical, Inc.'s Form D of 2025-07-11 names Carrie Powers, Jake Isenburg, Tom Kouchoukos and 10 more as its officers, directors or promoters.
Its new offerings report $25.40M sold across 4 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Carrie Powers is named as Executive Officer and Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Jake Isenburg is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Tom Kouchoukos is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Steve Jagodzinski is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Greg Smock is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Jerrod Krueger is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Heather Kotila is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Howard Root is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Ronald Eibensteiner is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Erwin Kelen is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Phil Nalbone is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Alan Woldt is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
Jeff Duncan is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 11 July 2025, one of 13 people that filing names.
13 people named on the filing — 8 holding an executive role and 5 as directors only.
Named as of the 2025-07-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Reprise Biomedical, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Reprise Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Reprise Biomedical, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Reprise Biomedical, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Reprise Biomedical, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Reprise Biomedical, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Minneapolis-St. Paul
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/reprise-biomedical-inc-form-d-25000001